Oxford BioDynamics (AIM:OBD) a biotechnology company developing targeted clinical diagnostic tests for immune health based on the EpiSwitch® 3D genomics platform, has announced that it has conditionally raised approximately £9.1 million by way of a Placing and Subscription and up to an additional £2.9 million through an Open Offer, with Shore Capital acting as Joint Bookrunner.

For further information please contact:  

Shore Capital +44 (0) 20 7408 4090

Corporate Advisory: Stephane Auton / John More / Iain Sexton

Corporate Broking: Fiona Conroy

For Shore Capital media enquiries, please contact:  

Adele Gilbert: +44 (0)74 8477 8331